Experts to Help Drive Improvements in Technology and Support the Development of New Solutions
REDWOOD CITY, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today announced that Drs. Donald S. (Buck) Cross, Edward Lazaga, Imran Mohiuddin, Radoslaw (Stefan) Kiesz, and Tea Acuff will be joining the Company’s Scientific and Medical Alliance Board. The new alliance members will apply their expertise to support the research and development process at Biotricity with a focus on scientific and clinical excellence.
“We are fortunate to add such high caliber physicians to our Scientific and Medical Alliance Board,” said Mr. Waqaas Al-Siddiq, Biotricity Founder and CEO. “Our new members are prestigious and talented physicians who bring a wide-range of skills to Biotricity. Their expertise and guidance will help us achieve our potential as the market leader in remote medical monitoring technology while fostering long-term growth and shareholder value.”
Biotricity is currently marketing and selling its flagship product Bioflux. The Company is leveraging the success of its RPM platform within Bioflux and applying it in remote patient monitoring solutions for a wide array of chronic conditions that will help aid disease management and improve patient engagement. The Company will work closely with its Alliance Board through the development process of its new remote monitoring solutions, and they will be the first to receive prototypes of Biotricity’s expanding portfolio of solutions when they become available. The Company will provide further details on its solution-specific collaboration with individual alliance members in the coming months.
About New Alliance Board Members:
Dr. Buck Cross specializes in complex and high-risk interventions and treatment of chronic total coronary occlusions and peripheral vascular disease. He is the National Medical Director for National Cardiovascular Partners, and a Fellow at the American College of Cardiology. Dr. Cross is board certified in Cardiovascular Disease and has practiced as an Interventional Cardiologist with Waco Cardiology Associates for the past 15 years.
Dr. Edward Lazaga specializes in Internal Medicine and has over 33 years of experience. He focuses on the diagnosis and treatment of both acute and chronic conditions. Dr. Lazaga is affiliated with multiple hospitals in Texas, including the Baptist Medical Center and Christus Santa Rosa Health System-San Antonio. He received his Internal Medicine certification from the University of Connecticut.
Dr. Imran Mohiuddin specializes in vascular surgery and has been practicing for 21 years. He received his board certification in Vascular Surgery from the Baylor College of Medicine. Dr. Mohiuddin was the first surgeon in Texas to implant the Crux Vena Cava Filter at the Houston Methodist Sugar Land Hospital. The filter is used in patients at risk for pulmonary embolism, a condition caused by a large blood clot migrating to the lungs.
Dr. Stefan Kiesz specializes in interventional cardiology and endovascular surgery. He is the Co-founder and deputy Chairman of the Supervisory Board of American Heart of Poland, and the Clinical Professor of Medicine and Cardiology at the University of Texas. Dr. Kiesz was the first surgeon in the world to perform a life-saving angioplasty; and was one of the world’s first pioneers in stenting of femoral and renal arteries. Today, he is the author of over 100 publications and abstracts in prestigious specialist journals.
Dr. Tea Acuff specializes in Cardiovascular and Thoracic Surgery. He is Chairman of the Cardiovascular Division at the Denton Regional Medical Center and a member of the Texas Medical Association and the Dallas County Medical Association. Dr. Acuff is the author of numerous publications and abstracts in prestigious specialist journals. He currently practices at North Texas Cardiothoracic Surgeons and has nearly 40 years’ experience.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.